Stiripentol efficacy against status epilepticus and associated mortality in mice

• Published in: Heliyon
• Main Authors: P. Girard, A. Bacq, P. Cloarec, C. Lesueur, M. Verleye, V. Castagné
• Format: Article
• Language: English
• Published: Elsevier 2024-08-01
• Subjects: Status epilepticus; Stiripentol; Convulsion; Mortality; Hyperammonemia; Valproic acid
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405844024108857

Stiripentol (STP, Diacomit©) is an antiseizure medication indicated for Dravet syndrome, a rare developmental and epileptic encephalopathy characterized by drug-resistant seizures, including status epilepticus (SE). SE is a life-threatening event that may lead to increased risk of morbidity and mortality. Here, we evaluated the effect of STP on SE and SE-associated mortality using a CBA mouse model induced by systemic administration of methionine sulfoximine (MSO), an irreversible inhibitor of glutamine synthetase. MSO induces convulsions, prolonged seizure (SE) and death, with an increase of blood ammonia level. A single acute intraperitoneal pretreatment with 200–300-400 mg/kg of STP significantly inhibited the number of seizures, SE occurrence and death in MSO-treated animals in a dose-dependent manner. Regarding blood ammonia level, STP significantly reduced by 41 % the hyperammonemia induced by MSO. In conclusion, our results show protective effects of STP to reduce and or suppress the occurrence of SE as well as its associated mortality in mice.